Ke Zuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ke Zuo has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Wentao Yang
Department of Pathology Fudan University Shanghai Cancer Center Shanghai China
5 shared publications Xiangjie Sun
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
3 shared publicationsPhilip P. Connell
Department of Radiation and Cellular Oncology, University of Chicago, Chicago, USA
2 shared publications- Rui Bi
Department of Pathology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
2 shared publications - Ruohong Shui
Department of Pathology Fudan University Shanghai Cancer Center Shanghai China
2 shared publications Shujin Liu
Shuwen Biotech Company Ltd, Deqing, China
2 shared publications
Latest Publications
- 22 April 2026
- Published by Wiley in Histopathology
- Vol. 89 (2) , 278-290
PLAG1 ‐rearranged uterine mesenchymal tumours: A study of 11 cases showing distinct histological features beyond myxoid morphology
Aims: PLAG1 gene fusions have been identified in a subset of uterine sarcomas and were historically associated with myxoid morphology. However, recent evidence shows that not all cases demonstrate myxoid features or conventional smooth muscle immunophenotype. Herein, we present 11 cases of PLAG1‐rearranged uterine mesenchymal tumours to further characterize their clinicopathologic, immunohistochemical and molecular profiles. Methods: Eleven cases of PLAG1 ‐rearranged uterine mesenchymal tumours were included from Fudan University Shanghai Cancer Center, comprising nine consultation referrals and two primary diagnoses. Clinicopathological features were reviewed, and all cases underwent targeted RNA sequencing with a 631‐gene panel. Results: The median patient age was 43 years (range: 31–58). Tumours occurred in the uterine corpus ( n = 10) or broad ligament ( n = 1), with a median size of 10 cm (range: 5.8–19 cm). Most presented at FIGO stage I. During follow‐up, 27.3% (3/11) of patients developed recurrence or metastasis. Histologic evaluation revealed significant heterogeneity: myxoid morphology in 54.5% (6/11), epithelioid morphology in 27.3% (3/11) and spindle cell morphology in 18.2% (2/11). Immunohistochemically, 81.8% (9/11) expressed at least one smooth muscle marker (desmin, h‐caldesmon or SMA). RNA sequencing confirmed PLAG1 rearrangements with multiple partners, including RAB2A , TRPS1 , PBX1 , PRLR , BOC , CSDE1 , TMEM68 , PHLPP1 , UBC , ESPL1 and NCOR2 . The most frequent fusions were TRPS1::PLAG1 (27.3%, n = 3) and CSDE1::PLAG1 (18.2%, n = 2). Conclusion: PLAG1 ‐rearranged uterine mesenchymal tumours demonstrate notable morphologic heterogeneity, predominantly presenting as myxoid leiomyosarcoma. We recommend using the integrated diagnostic term ‘ PLAG1 ‐rearranged uterine mesenchymal tumour with features of [specific morphology]’ to capture both the genetic alteration and histologic spectrum, accompanied by a comment regarding the limited experience and potential for recurrence.
- 22 April 2026
- Published by Wiley in Histopathology
- Vol. 89 (2) , 278-290
PLAG1 ‐rearranged uterine mesenchymal tumours: A study of 11 cases showing distinct histological features beyond myxoid morphology
Aims: PLAG1 gene fusions have been identified in a subset of uterine sarcomas and were historically associated with myxoid morphology. However, recent evidence shows that not all cases demonstrate myxoid features or conventional smooth muscle immunophenotype. Herein, we present 11 cases of PLAG1‐rearranged uterine mesenchymal tumours to further characterize their clinicopathologic, immunohistochemical and molecular profiles. Methods: Eleven cases of PLAG1 ‐rearranged uterine mesenchymal tumours were included from Fudan University Shanghai Cancer Center, comprising nine consultation referrals and two primary diagnoses. Clinicopathological features were reviewed, and all cases underwent targeted RNA sequencing with a 631‐gene panel. Results: The median patient age was 43 years (range: 31–58). Tumours occurred in the uterine corpus ( n = 10) or broad ligament ( n = 1), with a median size of 10 cm (range: 5.8–19 cm). Most presented at FIGO stage I. During follow‐up, 27.3% (3/11) of patients developed recurrence or metastasis. Histologic evaluation revealed significant heterogeneity: myxoid morphology in 54.5% (6/11), epithelioid morphology in 27.3% (3/11) and spindle cell morphology in 18.2% (2/11). Immunohistochemically, 81.8% (9/11) expressed at least one smooth muscle marker (desmin, h‐caldesmon or SMA). RNA sequencing confirmed PLAG1 rearrangements with multiple partners, including RAB2A , TRPS1 , PBX1 , PRLR , BOC , CSDE1 , TMEM68 , PHLPP1 , UBC , ESPL1 and NCOR2 . The most frequent fusions were TRPS1::PLAG1 (27.3%, n = 3) and CSDE1::PLAG1 (18.2%, n = 2). Conclusion: PLAG1 ‐rearranged uterine mesenchymal tumours demonstrate notable morphologic heterogeneity, predominantly presenting as myxoid leiomyosarcoma. We recommend using the integrated diagnostic term ‘ PLAG1 ‐rearranged uterine mesenchymal tumour with features of [specific morphology]’ to capture both the genetic alteration and histologic spectrum, accompanied by a comment regarding the limited experience and potential for recurrence.
- 15 December 2025
- Published by Wiley in Histopathology
- Vol. 88 (5) , 1075-1083
Apocrine encapsulated papillary carcinoma: a comprehensive clinicopathological analysis of 28 cases
Aims: Encapsulated papillary carcinoma (EPC) is characterized by neoplastic epithelial cells of low‐to‐intermediate nuclear grade arranged along fibrovascular cores. Classical EPC typically expresses oestrogen receptor (ER) and usually progesterone receptor (PR), while lacking human epidermal growth factor receptor 2 (HER2) overexpression and gene amplification. In contrast, apocrine encapsulated papillary carcinoma (AEPC), an exceptionally rare tumour with only a few well‐characterized cases, exhibits a triple‐negative phenotype (ER‐, PR‐, HER2‐). The purpose of this study is to investigate whether the clinicopathological characteristics of AEPC differ from those of classical EPC. Methods: Since 2014, 28 cases of AEPC have been identified at the Department of Pathology, Fudan University Shanghai Cancer Centre. We conducted a comprehensive clinicopathological evaluation and prognostic assessment in this case series. Results: All 28 patients in our study were female, with a median age at diagnosis of 61.5 years (range: 34–90). Fifteen cases were consultation referrals, while 13 cases were diagnosed and treated at our centre. Histologically, all AEPC cases demonstrated cystic architecture with papillary growth patterns. The papillary structures were lined by cells exhibiting uniform apocrine differentiation. The degree of cellular atypia ranged from mild‐to‐moderate, with no severe atypia identified. Notably, myoepithelial cells were absent in both the papillary structures and lesion peripheries. Among the 28 AEPC cases, 18 were non‐invasive, 8 demonstrated microinvasion (<1 mm), and 2 exhibited frank invasion (1–4 mm). The tumour cells exhibited a triple‐negative profile and most cases presented with diffuse positivity for androgen receptor (AR) and gross cystic disease fluid protein 15 (GCDFP15). The median Ki‐67 proliferation index was 10% (range: 5%–20%). Among the 28 patients, 19 received no adjuvant therapy, while 9 underwent postoperative radiotherapy and/or chemotherapy. With a median follow‐up of 44.3 months (range: 7.4–135.5 months) for 27 patients, no recurrences or metastases were observed. Conclusion: Classical EPC typically demonstrates favourable prognosis and is managed as ductal carcinoma in situ. In our study, none of the AEPC patients developed recurrence or metastasis, regardless of adjuvant therapy administration. Although AEPC exhibits a triple‐negative immunophenotype, it differs biologically from conventional triple‐negative breast cancer (TNBC). The indolent behaviour of AEPC aligns more closely with classical EPC rather than TNBC. Therefore, it may be more appropriate to treat AEPC patients using the same strategies applied to classical EPC.
- 15 December 2025
- Published by Wiley in Histopathology
- Vol. 88 (5) , 1075-1083
Apocrine encapsulated papillary carcinoma: a comprehensive clinicopathological analysis of 28 cases
Aims: Encapsulated papillary carcinoma (EPC) is characterized by neoplastic epithelial cells of low‐to‐intermediate nuclear grade arranged along fibrovascular cores. Classical EPC typically expresses oestrogen receptor (ER) and usually progesterone receptor (PR), while lacking human epidermal growth factor receptor 2 (HER2) overexpression and gene amplification. In contrast, apocrine encapsulated papillary carcinoma (AEPC), an exceptionally rare tumour with only a few well‐characterized cases, exhibits a triple‐negative phenotype (ER‐, PR‐, HER2‐). The purpose of this study is to investigate whether the clinicopathological characteristics of AEPC differ from those of classical EPC. Methods: Since 2014, 28 cases of AEPC have been identified at the Department of Pathology, Fudan University Shanghai Cancer Centre. We conducted a comprehensive clinicopathological evaluation and prognostic assessment in this case series. Results: All 28 patients in our study were female, with a median age at diagnosis of 61.5 years (range: 34–90). Fifteen cases were consultation referrals, while 13 cases were diagnosed and treated at our centre. Histologically, all AEPC cases demonstrated cystic architecture with papillary growth patterns. The papillary structures were lined by cells exhibiting uniform apocrine differentiation. The degree of cellular atypia ranged from mild‐to‐moderate, with no severe atypia identified. Notably, myoepithelial cells were absent in both the papillary structures and lesion peripheries. Among the 28 AEPC cases, 18 were non‐invasive, 8 demonstrated microinvasion (<1 mm), and 2 exhibited frank invasion (1–4 mm). The tumour cells exhibited a triple‐negative profile and most cases presented with diffuse positivity for androgen receptor (AR) and gross cystic disease fluid protein 15 (GCDFP15). The median Ki‐67 proliferation index was 10% (range: 5%–20%). Among the 28 patients, 19 received no adjuvant therapy, while 9 underwent postoperative radiotherapy and/or chemotherapy. With a median follow‐up of 44.3 months (range: 7.4–135.5 months) for 27 patients, no recurrences or metastases were observed. Conclusion: Classical EPC typically demonstrates favourable prognosis and is managed as ductal carcinoma in situ. In our study, none of the AEPC patients developed recurrence or metastasis, regardless of adjuvant therapy administration. Although AEPC exhibits a triple‐negative immunophenotype, it differs biologically from conventional triple‐negative breast cancer (TNBC). The indolent behaviour of AEPC aligns more closely with classical EPC rather than TNBC. Therefore, it may be more appropriate to treat AEPC patients using the same strategies applied to classical EPC.
- 19 November 2021
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 191 (2) , 335-344
qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer
Purpose Cumulative evidence suggests that the addition of platinum agents as neoadjuvant chemotherapy (NACT) could improve the pathologic complete response (pCR) rate in triple-negative breast cancer (TNBC). We aimed to develop a DNA homologous recombination (HR)-associated gene expression score to predict tumor sensitivity to platinum-based NACT in TNBC. Methods A retrospective cohort of 127 patients who were diagnosed with TNBC and received platinum-based NACT in Fudan University Shanghai Cancer Center from 2012 to 2017 was included in this study. Using quantitative reverse transcription-polymerase chain reaction (qRT-PCR), the expression levels of eight HR-associated genes were analyzed from formalin-fixed paraffin-embedded core-needle biopsy samples obtained before NACT. A random forest model was built to estimate the weight of each gene expression level and clinicopathological factors. The training set was used to modulate parameters and select the best model. The performance of the final model was evaluated in the validation set. Results A 4-gene (BRCA1, XRCC5, PARP1, and RAD51) scoring system was developed. TNBC patients with a higher score had a nearly fourfold likelihood of achieving pCR to platinum-based NACT compared with patients with a lower score [odds ratio (OR) = 3.878; P < 0.001]. At the cutoff value of − 2.644, the 4-gene scoring system showed high sensitivity in predicting pCR in the breast (93.0%) and pCR in the breast/axilla (91.8%), while at the cutoff value of − 1.969, the 4-gene score showed high specificity for pCR in the breast (85.7%) and pCR in the breast/axilla (80.8%). Conclusion The qRT-PCR-based 4-gene score has the potential to predict pCR to platinum-based NACT in TNBC.
- 19 November 2021
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 191 (2) , 335-344
qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer
Purpose Cumulative evidence suggests that the addition of platinum agents as neoadjuvant chemotherapy (NACT) could improve the pathologic complete response (pCR) rate in triple-negative breast cancer (TNBC). We aimed to develop a DNA homologous recombination (HR)-associated gene expression score to predict tumor sensitivity to platinum-based NACT in TNBC. Methods A retrospective cohort of 127 patients who were diagnosed with TNBC and received platinum-based NACT in Fudan University Shanghai Cancer Center from 2012 to 2017 was included in this study. Using quantitative reverse transcription-polymerase chain reaction (qRT-PCR), the expression levels of eight HR-associated genes were analyzed from formalin-fixed paraffin-embedded core-needle biopsy samples obtained before NACT. A random forest model was built to estimate the weight of each gene expression level and clinicopathological factors. The training set was used to modulate parameters and select the best model. The performance of the final model was evaluated in the validation set. Results A 4-gene (BRCA1, XRCC5, PARP1, and RAD51) scoring system was developed. TNBC patients with a higher score had a nearly fourfold likelihood of achieving pCR to platinum-based NACT compared with patients with a lower score [odds ratio (OR) = 3.878; P < 0.001]. At the cutoff value of − 2.644, the 4-gene scoring system showed high sensitivity in predicting pCR in the breast (93.0%) and pCR in the breast/axilla (91.8%), while at the cutoff value of − 1.969, the 4-gene score showed high specificity for pCR in the breast (85.7%) and pCR in the breast/axilla (80.8%). Conclusion The qRT-PCR-based 4-gene score has the potential to predict pCR to platinum-based NACT in TNBC.
- Open Access
- 13 May 2021
- Published by Springer Nature in Research Square
qRT-PCR-based DNA homologous recombination associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer
PurposeCumulative evidences suggested the addition of platinum agents as neoadjuvant chemotherapy (NACT) could improve pathologic complete response (pCR) in triple-negative breast cancers (TNBC). We tried to develop a DNA homologous recombination (HR) associated gene expression score to predict tumor sensitivity to platinum-based NACT in TNBC.MethodsA retrospective cohort of 127 TNBC patients, who were diagnosed and received platinum-based NACT in Fudan University Shanghai Cancer Center from 2012 to 2017, was included in this study. By using quantitative reverse transcription-polymerase chain reaction (qRT-PCR), the expression level of eight HR associated genes was analyzed from the formalin-fixed paraffin-embedded core needle biopsy samples which obtained before NACT. A random forest model was built to estimate the weight of each gene expression level and clinical-pathological factors. The training set was used to modulate parameters and select the best model. The performance of the final model was evaluated in the validation set. ResultsA 4-gene (BRCA1, XRCC5, PARP1, RAD51) expression scoring system was developed. TNBC with higher score had nearly quadruple likelihood to achieve pCR to platinum-based NACT compared with a lower score [odds ratio (OR)=3.878; P<0.001]. At the cut-off value of -2.644, the 4-gene score system showed high sensitivity in predicting pCR in breast (93.0%) and pCR in both breast/axilla (91.8%), while, at the cut-off value of -1.969, the 4-gene score showed high specificity for pCR in breast (85.7%) and pCR in both breast/axilla (80.8%). ConclusionThe qRT-PCR-based 4-gene score has the potential to predict pCR to platinum-based NACT in TNBC.
- 13 May 2021
- Published by Springer Nature in Research Square
Open AccessqRT-PCR-based DNA homologous recombination associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer
PurposeCumulative evidences suggested the addition of platinum agents as neoadjuvant chemotherapy (NACT) could improve pathologic complete response (pCR) in triple-negative breast cancers (TNBC). We tried to develop a DNA homologous recombination (HR) associated gene expression score to predict tumor sensitivity to platinum-based NACT in TNBC.MethodsA retrospective cohort of 127 TNBC patients, who were diagnosed and received platinum-based NACT in Fudan University Shanghai Cancer Center from 2012 to 2017, was included in this study. By using quantitative reverse transcription-polymerase chain reaction (qRT-PCR), the expression level of eight HR associated genes was analyzed from the formalin-fixed paraffin-embedded core needle biopsy samples which obtained before NACT. A random forest model was built to estimate the weight of each gene expression level and clinical-pathological factors. The training set was used to modulate parameters and select the best model. The performance of the final model was evaluated in the validation set. ResultsA 4-gene (BRCA1, XRCC5, PARP1, RAD51) expression scoring system was developed. TNBC with higher score had nearly quadruple likelihood to achieve pCR to platinum-based NACT compared with a lower score [odds ratio (OR)=3.878; P<0.001]. At the cut-off value of -2.644, the 4-gene score system showed high sensitivity in predicting pCR in breast (93.0%) and pCR in both breast/axilla (91.8%), while, at the cut-off value of -1.969, the 4-gene score showed high specificity for pCR in breast (85.7%) and pCR in both breast/axilla (80.8%). ConclusionThe qRT-PCR-based 4-gene score has the potential to predict pCR to platinum-based NACT in TNBC.
- Open Access
- 1 December 2020
- Published by Elsevier in Laboratory Investigation
- Vol. 33 (12) , 2473-2482
Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas
- 1 December 2020
- Published by Elsevier in Laboratory Investigation
- Vol. 33 (12) , 2473-2482
Open AccessInvasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas
- 8 July 2017
- Published by Wolters Kluwer Health
- Vol. 46 (7) , 476-480
[Correlation between androgen receptor expression and surrogate molecular subtypes in invasive breast carcinoma].
Objective: To investigate androgen receptor(AR)expression in invasive breast carcinoma and the correlation with surrogate molecular breast carcinoma subtypes. Methods: Immunohistochemical staining of AR and other biomarkers was performed in a cohort of 870 cases of primary invasive breast carcinomas collected from August to December, 2016. The association of AR expression with different histological and surrogate molecular subtypes was analyzed. Results: The positive expression rate of AR in the immunohistochemistry-based surrogate subtypes was 96.3%(207/215) for Luminal A, 89.8%(378/421) for Luminal B, 82.4%(75/91) for HER2 overexpression and 37.1%(53/143) for triple negative breast carcinoma, with significant differences among the four groups (P<0.01). AR correlated positively with the expression of ER(P<0.01), PR(P<0.01), HER2(P=0.007), GATA3(P<0.01), GCDFP15(P<0.01)and mammaglobin(P<0.01), while negatively with the expression of Ki-67(P<0.01), CK5/6(P<0.01)and CK14(P<0.01). Conclusions: AR exhibits a high expression in invasive breast carcinoma, which is mainly correlated with ER-positive breast carcinoma. Regardless of the relatively low expression rate, AR is a potential therapeutic target in triple negative breast carcinoma.
- 8 July 2017
- Published by Wolters Kluwer Health
- Vol. 46 (7) , 476-480
[Correlation between androgen receptor expression and surrogate molecular subtypes in invasive breast carcinoma].
Objective: To investigate androgen receptor(AR)expression in invasive breast carcinoma and the correlation with surrogate molecular breast carcinoma subtypes. Methods: Immunohistochemical staining of AR and other biomarkers was performed in a cohort of 870 cases of primary invasive breast carcinomas collected from August to December, 2016. The association of AR expression with different histological and surrogate molecular subtypes was analyzed. Results: The positive expression rate of AR in the immunohistochemistry-based surrogate subtypes was 96.3%(207/215) for Luminal A, 89.8%(378/421) for Luminal B, 82.4%(75/91) for HER2 overexpression and 37.1%(53/143) for triple negative breast carcinoma, with significant differences among the four groups (P<0.01). AR correlated positively with the expression of ER(P<0.01), PR(P<0.01), HER2(P=0.007), GATA3(P<0.01), GCDFP15(P<0.01)and mammaglobin(P<0.01), while negatively with the expression of Ki-67(P<0.01), CK5/6(P<0.01)and CK14(P<0.01). Conclusions: AR exhibits a high expression in invasive breast carcinoma, which is mainly correlated with ER-positive breast carcinoma. Regardless of the relatively low expression rate, AR is a potential therapeutic target in triple negative breast carcinoma.